Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT - Trial NCT06349317
Access comprehensive clinical trial information for NCT06349317 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yongyi Zeng and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
Interventional
combination product
Sponsor & Location
Yongyi Zeng
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Timeline & Enrollment
Phase 2
May 01, 2024
Jun 01, 2026
Primary Outcome
1-year Event-Free Survival (EFS) rate
Summary
This study is an open-label, single-arm prospective clinical trial that evaluates the
 efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with
 perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular
 carcinoma with portal vein tumor thrombus.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06349317
Non-Device Trial